Receiving a positive drug test result is one of the highest-stakes moments in a DOT drug and alcohol testing program. The steps the Designated Employer Representative (DER) takes in the minutes and hours after receiving that result determine whether the employer meets its compliance obligations or creates audit exposure, liability risk, and potential regulatory violations.
This guide walks through each step the DER must take following a verified positive drug test result under 49 CFR Part 40, including the immediate removal requirement, Clearinghouse reporting, SAP referral, documentation, and return-to-duty coordination.
Why This Matters
A verified positive drug test is one of the highest-liability events in a DOT testing program. Delaying removal from safety-sensitive duties, even by a few hours, or failing to document each step can create audit findings, increase employer liability, and complicate future legal proceedings. Having a documented response process protects both the employer and the integrity of the testing program.
Key Takeaways
- The MRO reports the verified positive result directly to the DER, not to the employee or to HR generally. The DER is the first employer contact for every verified result.
- Upon receiving a verified positive result, the DER must immediately remove the employee from all safety-sensitive functions per 49 CFR Part 40.305. There is no review window and no discretion to delay.
- An employee’s split specimen request does not suspend the removal requirement. The employee remains off duty while the split specimen retest is pending.
- For FMCSA-regulated CDL drivers, the MRO reports positive drug and alcohol results to the FMCSA Clearinghouse. The DER is responsible for reporting refusals to the Clearinghouse within two business days.
- The DER does not receive the employee’s prescription information or medical explanation from the MRO interview. Confidentiality protections built into 49 CFR Part 40 limit the DER to the verified result and drug identified.
- The DER’s documentation of each step is a compliance record. Gaps in documentation become audit findings.
What the DER Receives From the MRO
Under 49 CFR Part 40.163, the Medical Review Officer reports verified results directly to the DER. This is a regulatory requirement, not an administrative preference. The MRO does not report to a general HR inbox, to the employee, or to anyone else at the employer unless HR holds the DER designation.
What the MRO reports to the DER is limited by the confidentiality protections in 49 CFR Part 40, Subpart P. The DER receives the verified result category and the drug or substance identified. The DER does not receive the employee’s prescription information, the content of the medical interview, or any other protected health information that arose during the MRO’s review process.
Result categories the DER may receive from the MRO include: Positive, Negative, Dilute Negative, Dilute Positive, Substituted, Adulterated, Invalid, Canceled, and Refusal to Test. For a full explanation of each result category and how the MRO review process works, see What Is an MRO?
For the purposes of this guide, the focus is on a verified positive or dilute positive result, the results that require the most immediate and consequential DER response.
Step 1: Immediately Remove the Employee From Safety Sensitive Duties
Upon receiving a verified positive drug test result from the MRO, the DER must immediately remove the employee from all safety-sensitive functions. This requirement is established under 49 CFR Part 40.305 and applies without exception.
Immediately means immediately. There is no review period. There is no window during which the DER can wait to see what the employee says, consult with HR about employment consequences, or allow the employee to complete a shift. The moment the DER receives the verified result, the employee must be removed from safety-sensitive duties.
This removal obligation is separate from any employment decision. The DER does not need to have decided whether the employee will be terminated, suspended, or placed on leave before removing them from safety-sensitive functions. Removal from safety-sensitive duty is a compliance action. What happens to the employee’s employment is an HR decision made separately and afterward.
The same immediate removal requirement applies to: a confirmed alcohol test result of 0.02 or greater, a report of a refusal to test, and any other DOT drug and alcohol program violation. For a full overview of the DER’s authority and removal obligations, see DER Support Services.
Step 2: Inform the Employee of the Result and Their Rights
After the removal is in effect, the DER notifies the employee of the verified positive result. The notification should be done promptly and in a manner consistent with the employer’s drug and alcohol testing policy and any applicable HR procedures. In most cases, the employee will have already been notified of the verified positive result during their interview with the MRO; only in cases where the MRO could not reach the employee would they not have received the determination directly from the MRO.
It is the MRO’s obligation, not the DER’s, to inform the employee of their right to request split-specimen testing. The MRO communicates this to the employee during the verification interview. The DER does not carry an independent obligation to notify the employee of these rights, but should be aware of them to support the process if questions arise.
Split specimen request: The employee has 72 hours from receiving notification of the verified positive result to request that Bottle B be tested at a second SAMHSA-certified laboratory. It is generally the donor who contacts the MRO directly to request split specimen testing, and the MRO then initiates the split specimen test. The DER is often kept in the loop but does not carry responsibility for seeing this process through. If the split specimen does not confirm the positive result, the test is canceled. If it does confirm the result, the positive stands.
A critical point for DERs: the split specimen request does not suspend the removal requirement. The employee remains off safety-sensitive duty while the split-specimen retest is pending. The DER should document both the removal and the split specimen request in the testing record.
Step 3: Clearinghouse Reporting for FMCSA Regulated CDL Drivers
For FMCSA-regulated CDL drivers, the FMCSA Drug and Alcohol Clearinghouse is a federal database that must be updated following a drug or alcohol program violation.
Under the Clearinghouse reporting structure for DOT drug testing, the MRO reports verified positive drug test results directly to the Clearinghouse. The DER is responsible for reporting the following to the Clearinghouse: refusals to test, alcohol confirmation test results of 0.04 BAC or greater, and actual-knowledge violations (situations where the employer has direct knowledge of a DOT drug or alcohol rule violation, such as an employee reporting to work under the influence). These are the DER’s Clearinghouse reporting obligations and are distinct from the MRO’s obligation to report verified positive drug test results.
For employers working through PROCOM’s TPA services, PROCOM provides Clearinghouse support to ensure reporting is completed correctly and within required timeframes. However, the compliance obligation rests with the employer. DERs should confirm that Clearinghouse entries are made for every qualifying violation and maintain documentation of the reporting date.
Employers with drivers operating under other DOT agency programs should confirm agency-specific reporting requirements following a positive result. The FMCSA Clearinghouse is FMCSA-specific and does not apply to other DOT modes. Both the FAA and USCG have their own distinct reporting obligations that DERs in those industries must understand. For FAA-regulated employers, a positive test or refusal involving an employee who holds or would be required to hold an airman medical certificate triggers specific notification requirements, including MRO reporting to the Federal Air Surgeon within two working days. FAA employers also have annual MIS reporting obligations. For USCG-regulated employers, under 46 CFR § 16.201, a failed drug test involving a credentialed mariner must be reported in writing to the nearest Coast Guard Officer in Charge, Marine Inspection. The return-to-work requirements under 46 CFR Part 16 are also more specific than the standard DOT framework: the individual may not return to any safety-sensitive vessel duties until the MRO has determined they are drug-free and that the risk of subsequent use is sufficiently low to justify return, the individual must agree to a minimum of six unannounced follow-up tests in the first year after returning to duty, and credentialed mariners remain subject to suspension and revocation proceedings under 46 CFR Part 5 regardless of whether they complete the return-to-duty process. DERs in FAA- or USCG-regulated programs should confirm the full reporting and return-to-work requirements applicable to their specific regulatory context.
Need Help Managing Positive Drug Test Results?
PROCOM helps employers navigate every step of the process, including:
✔ Immediate DER guidance
✔ In-house MRO services
✔ Clearinghouse support
✔ SAP referrals
✔ Return-to-duty coordination
✔ Audit-ready documentation
Start your DOT testing program or strengthen your current process today.
📞 303-325-3010 | 📧 michelle@procomtesting.com
Step 4: Refer the Employee to a Substance Abuse Professional
Following a verified positive drug test result, the employer is required to refer the employee to a Substance Abuse Professional (SAP) for evaluation. The SAP is a licensed professional qualified under 49 CFR Part 40, Subpart O, who evaluates employees who have violated DOT drug and alcohol requirements and determines the clinical interventions and follow-up testing required before the employee can return to safety-sensitive duty.
What the DER does: The DER provides the employee with a list of SAPs or a resource for finding a qualified SAP. The employee, not the employer, selects the SAP. The DER does not choose the SAP for the employee. Under 49 CFR Part 40, the employee has the right to select a qualified SAP from the employer’s list or from any available qualified provider.
What the SAP does: The SAP conducts a face-to-face evaluation, determines the appropriate treatment or education plan, and specifies the follow-up testing requirements. Under 49 CFR Part 40.309, the SAP must specify a minimum of six unannounced directly observed follow-up tests in the first 12 months following return to safety-sensitive duty. The SAP’s determination is independent of the employer and is not subject to employer override.
In most cases where a positive result leads to termination, the DER’s role ends with the initial SAP referral. If the employee remains with the employer and pursues return-to-duty, the DER coordinates the return-to-duty collection and manages the follow-up testing calendar.
Step 5: Coordinate Return to Duty Testing If the Employee Remains
If the employee is not terminated and pursues the return-to-duty process, the DER coordinates each stage following the SAP’s final evaluation. This process cannot begin until the SAP has completed the final evaluation and determined that the employee has complied with the recommended treatment or education requirements. The DER should receive a clearance letter from the SAP enabling the Return-to-duty testing and containing the specific requirements for the Follow-up testing schedule.
Return-to-duty test: The return-to-duty drug test must be directly observed. The DER coordinates the collection through the C/TPA and confirms that the correct directly observed protocol is applied. Upon receiving a verified negative result from the MRO, the DER may authorize the employee’s return to safety-sensitive functions. Keep in mind that sometimes the SAP will require the Return-to-duty testing will have both an alcohol and a drug component and both results must be received and negative prior to the employee resuming safety sensitive functions.
Follow-up testing: The DER manages the follow-up testing schedule in coordination with the C/TPA. The SAP’s report specifies the minimum number of tests and the timeframe. Follow-up tests must be unannounced and directly observed. The DER maintains documentation of each follow-up test completion.
For FMCSA-regulated CDL drivers, the employer should confirm that all Clearinghouse entries related to the return-to-duty process are current before allowing the employee to return to a safety-sensitive role. Upon successful completion of the Return to Duty Process (including all required Follow-up tests) the DER needs to certify the completion in the Clearinghouse.
Step 6: Documentation the DER Must Maintain
Every step in the DER’s positive result response must be documented. Compliance audits consistently reveal that employers took the correct actions, but cannot prove it because documentation was incomplete or disorganized. The DER’s documentation is the compliance record.
For a positive drug test result, the DER should maintain:
- The MRO’s written result report, including the date and time the DER received the result
- Documentation of when the employee was removed from safety-sensitive duties; date, time, and method of notification
- Any split specimen request and its outcome
- Clearinghouse reporting confirmation for FMCSA-regulated drivers
- The SAP referral documentation, including the list of SAPs provided to the employee
- Return-to-duty and follow-up testing records if the employee pursued the RTD process
- Any Clearinghouse updates related to return-to-duty completion
Under DOT regulations, most drug and alcohol testing records must be retained for five years. Negative and canceled test results are retained for two years. The DER should confirm retention schedules with the employer’s legal counsel and maintain organized files that can be produced immediately upon audit request.
What the DER Cannot Do
Several boundaries are worth stating clearly because DERs sometimes encounter pressure or confusion around these points:
The DER cannot delay the removal. A manager’s request to let the employee finish a shift, complete a delivery, or remain on duty until a replacement is found does not alter the DER’s obligation. The removal is required by federal regulation.
The DER cannot overturn the MRO’s verified result. Only the MRO can change a verified result, and only through the regulatory review process. The DER receiving the verified result has no authority to second-guess or reverse it.
The DER cannot conduct the SAP evaluation. The SAP’s clinical determination is independent. The DER provides the referral and the list of qualified SAPs. What the SAP determines is not subject to employer input or override.
The DER cannot share the employee’s result with anyone who does not need to know. DOT confidentiality requirements restrict disclosure of results to individuals directly involved in the testing program administration. The DER should consult the employer’s policy and legal counsel regarding who within the organization is authorized to receive result information.
Need Help Managing Your Positive Result Protocol?
PROCOM provides:
- ✔ Direct DER support – no ticketing system
- ✔ In-house MRO services for faster verified results
- ✔ Clearinghouse reporting support for FMCSA-regulated programs
- ✔ Consortium and TPA management, including SAP referral coordination
- ✔ Audit-ready documentation and recordkeeping guidance
Contact PROCOM to establish a company testing account or discuss how PROCOM’s TPA services support your DER. DER Support Services | Consortium and TPA Services
📞 303-325-3010 | 📧 michelle@procomtesting.com
Frequently Asked Questions About Positive Drug Test Results
In most cases, the employee is already aware of the positive result before or at the same time the DER is notified. The MRO contacts the employee directly during the verification process and conducts a medical interview; the employee is typically informed of the outcome during that conversation. The MRO then reports the verified result to the DER. The employee would not yet know the result only in cases where the MRO was unable to reach them, in which case the MRO reports the positive to the DER and the DER then notifies the employee.
No. Removal from safety-sensitive duties is required immediately upon receipt of a verified positive result. A pending split specimen request does not suspend the removal obligation. The employee remains off safety-sensitive duty while the split specimen retest is in process.
In most cases the MRO’s verified result has already accounted for any prescription the employee raised during the interview. However, there are instances where an employee later remembers a prescription they forgot to mention, or realizes they had documentation they didn’t present. In those situations, the employee can reach back out to the MRO directly and present their case. In select instances, results have been overturned this way. The critical point for the DER is that they cannot overturn a verified positive result under any circumstance. The DER can ask the MRO to conduct another review, but that is the full extent of their role. The final determination rests with the MRO alone.
Failure to remove an employee from safety-sensitive duties following a verified positive result is a regulatory violation under 49 CFR Part 40.305. It creates compliance exposure for the employer and can result in findings during DOT audits. If an employee continues to operate in a safety-sensitive role after a verified positive and is involved in an accident, the employer’s exposure increases significantly.
Generally, employers do not pay for SAP evaluations or the treatment they may require. These costs are typically the responsibility of the employee. While DOT regulations do not specifically assign cost responsibility, the practical standard in most programs is that the employee bears the financial obligation for both the evaluation and any required follow-up treatment. Employers should address cost allocation explicitly in their drug and alcohol testing policy to avoid ambiguity when a positive result situation arises.
There is no fixed minimum or maximum timeline for the return-to-duty process. As a practical rule of thumb, PROCOM advises employers to plan for two weeks on the low end and two months on the high end, though cases outside that range do occur in both directions. The timeline depends on the SAP’s evaluation findings, the treatment or education required, the employee’s compliance with the SAP’s recommendations, and the scheduling of the return-to-duty collection and MRO review. The DER manages the employer’s side of the process and coordinates with the C/TPA for collection scheduling.
Related Services: DER Support Services | Consortium and TPA Services | DOT Drug and Alcohol Testing | What Is an MRO? | View All Services
Compliance Resources: 49 CFR Part 40 | FMCSA Drug and Alcohol Rules | FMCSA Clearinghouse | DOT Agency Requirements
Service Areas: Denver | Colorado Springs | Pueblo | Grand Junction | Glenwood Springs | View All Service Areas
Regulatory Disclaimer: This content is provided for general informational and educational purposes regarding DOT and workplace drug and alcohol testing requirements. It does not constitute legal advice, official DOT regulatory interpretation, or company-specific compliance guidance. DOT drug and alcohol testing regulations are established under 49 CFR Part 40 and DOT agency-specific regulations and are subject to amendment. Always verify you are applying current regulations and consult qualified legal counsel for definitive compliance requirements. PROCOM Testing provides DOT and non-DOT drug and alcohol testing services in accordance with 49 CFR Part 40. Compliance with drug and alcohol testing regulations is the employer’s responsibility.
PROCOM Testing | DOT-Qualified Collectors | SAMHSA-Certified Lab Partnerships | In-House MRO Services
